BCL2L1 and central nervous system cancer: Recently, a Bcl-x SSO, modified using 2′-O-methoxyethyl-phosphorothioate and delivered with a cationic lipid into glioma and astrocyte cell lines, modulated the RNA splicing of Bcl-x pre-mRNA in glioma cell lines [75].